Cubist Systematic Strategies’s Praxis Precision Medicines PRAX Stock Holding History

Cubist Systematic Strategies’s Portfolio PRAX Stock Details PRAX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-1,195	Closed	-$42.6K	–	4305
2022 Q4	$42.6K	Sell	1,195 -6,636	-85%	-$207K	﹤0.01%	3925
2022 Q3	$267K	Sell	7,831 -161	-2%	-$8.02K	﹤0.01%	3590
2022 Q2	$294K	Buy	7,992 +6,921	+646%	+$739K	﹤0.01%	3449
2022 Q1	$164K	Buy	1,071 +431	+67%	+$88.5K	﹤0.01%	3102
2021 Q4	$189K	Buy	640 +146	+30%	+$42.8K	﹤0.01%	3051
2021 Q3	$137K	Sell	494 -2,692	-84%	-$730K	﹤0.01%	2679
2021 Q2	$874K	Buy	3,186 +2,974	+1,403%	+$1.06M	0.01%	1674
2021 Q1	$104K	Hold	212	–	–	﹤0.01%	2636
2020 Q4	$175K	Buy	+212	New	+$124K	﹤0.01%	2287

Other funds holding PRAX

VCIM

Velan Capital Investment Management Alpharetta, Georgia $160M AUM 517.12% 1-Year Est. Return

KCM

Kingdon Capital Management New York $911M AUM 51.11% 1-Year Est. Return

APM

Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Verition Fund Management Greenwich, Connecticut $15.4B AUM 30.69% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

TLP

Tri Locum Partners New York $713M AUM 68.92% 1-Year Est. Return

PHS

PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

GPP

Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return

Cubist Systematic Strategies's PRAX Position: Q1 2023 in Review

Cubist Systematic Strategies sold out of Praxis Precision Medicines (PRAX) in Q1 2023, closing a stake of 1,195 shares — an estimated $42.6K sold.

Cubist Systematic Strategies first reported a position in PRAX in Q4 2020 and held it in 9 quarters. The position peaked at $874K in Q2 2021. 86 funds tracked by Wall St. Rank hold PRAX as of Q1 2023.

Cubist Systematic Strategies reported no remaining Praxis Precision Medicines position as of Q1 2023 after selling out during the quarter.
Cubist Systematic Strategies sold 1,195 Praxis Precision Medicines shares in Q1 2023, an estimated $42.6K.
Cubist Systematic Strategies first reported a position in Praxis Precision Medicines in Q4 2020 and held it in 9 quarters.
Cubist Systematic Strategies's Praxis Precision Medicines position peaked at $874K in Q2 2021.
86 funds tracked by Wall St. Rank held Praxis Precision Medicines as of Q1 2023.

Based on Cubist Systematic Strategies's 13F filing for Q1 2023, filed 15 May 2023.